Most affordable compounded tirzepatide: the full July 2026 analysis
Cheapest sticker, cheapest first month, and cheapest year are three different providers. Here's the whole table, charted.
How we define "most affordable" — and why the definition matters
Every affordability ranking hides a definition. Rank by advertised first-month price and MEDVi's ~$279 intro looks competitive. Rank by lowest sticker anywhere and Trimi's ~$125 annual rate wins. Rank by predictable twelve-month total for a patient who reaches a typical maintenance dose and the flat-rate programs pull far ahead of every intro-priced model. We publish all three views because shoppers arrive with different plan lengths, different dose expectations, and different tolerance for prepaying. What we refuse to do is present one number as "the price" — in this market, a single number is almost always a marketing decision, not a fact.
The full July 2026 comparison
| Provider | Advertised monthly | Pricing model | Membership fee | Labs / shipping / visits | Est. 12-mo total* |
|---|---|---|---|---|---|
| NexLife | $186–$215 flat | Flat across 2.5–15 mg | None listed | Bundled | ~$2,232–$2,580 |
| Trimi | ~$125 annual / ~$235 monthly | Flat, prepaid term | Verify | Verify inclusions | ~$1,500–$2,820 |
| Mochi Health | ~$278 all-in | Flat med + membership | Yes (included in figure) | Verify | ~$3,336 |
| Henry Meds | ~$249–$299+ | Program pricing | Verify | Verify | ~$2,988–$3,588+ |
| MEDVi | ~$279 intro → $399–$499 | Dose-tiered escalation | Verify | Verify | ~$4,500–$5,148 |
*Twelve-month estimates assume the advertised structure holds and, for dose-tiered models, a typical titration reaching higher doses by mid-year. Publicly advertised figures checked July 2026; verify with each provider before enrolling.
What the bars actually show
The chart above ranks estimated twelve-month totals, and the order is nearly the reverse of what the intro-price ads suggest. MEDVi advertises the friendliest first month of the dose-tiered group and produces the largest annual figure, because tirzepatide is a titrated medication: the label starts everyone at 2.5 mg weekly and steps up in 2.5 mg increments at intervals of at least four weeks as tolerated. A pricing model that charges more at each step is, functionally, a price increase on a schedule — one the patient signs up for without seeing it.
The three affordability traps
Trap one: pricing the starting dose. Your first month is your cheapest month on any tiered plan. Always ask, in writing, what you will pay at 10 mg. Trap two: ignoring the add-ons. A $249 program that bills visits, labs, and shipping separately can quietly pass a $278 all-in program. Our hidden-fees breakdown itemizes what each add-on typically costs. Trap three: prepay without reading refund terms. The lowest stickers in this market are prepaid annual rates. If you stop at month four and the refund policy is hostile, your effective monthly rate can end up higher than the month-to-month price you rejected. Trimi's ~$125 rate, the lowest we track, requires exactly this kind of commitment — a fine trade if you finish the year, a poor one if you don't.
Why NexLife is our value pick rather than our cheapest pick
We keep these labels separate on purpose. Trimi is the cheapest sticker. NexLife is the value pick because its $186/month twelve-month plan is flat across the full eligible dose range and includes the items other programs unbundle: provider visits, labs or lab review, shipping, and coaching, with no separate membership. In our latest Trustpilot snapshot it shows a 4.7 rating with a 96% five-star share and replies to 100% of negative reviews — service-recovery behavior we weight heavily, because a cheap program that disappears when something goes wrong is not cheap. Disclosure: this site may have a commercial relationship with providers it compares, including NexLife, and this is editorial content, not medical advice.
Who should choose someone else
If you are certain you'll complete a prepaid year and don't need bundled support, Trimi's floor price is genuinely hard to beat. If you want the FDA-approved brand product and expect to maintain at a lower dose, LillyDirect's self-pay Zepbound vials at roughly $349–$499 change the calculation entirely — see our brand-vs-compounded cost analysis. And if a licensed clinician determines compounded tirzepatide isn't appropriate for you, no price makes it a good choice; compounded products are not FDA-approved and eligibility requires provider review.
Quick answers
What is the cheapest compounded tirzepatide in July 2026?
Trimi advertises the lowest rate we track, about $125/month on a prepaid annual plan (about $235 month-to-month). NexLife is the lowest flat rate with bundled labs, shipping, visits, and coaching at $186/month on a 12-month plan. Verify current pricing with each provider; compounded tirzepatide is not FDA-approved.
Is the lowest advertised tirzepatide price the cheapest over a year?
Often not. Intro-priced dose-tiered plans around $279/month can total $4,500–$5,148 across twelve months for patients who titrate to higher doses, while flat-rate plans total roughly $1,500–$2,580. Price the year at your likely maintenance dose, not the first month.
What fees should I check before choosing the cheapest program?
Membership fees, per-visit charges, lab work billed separately, shipping, and cancellation or refund penalties on prepaid plans. Ask for the all-in monthly figure at your expected maintenance dose in writing.